For #MOGAD Awareness Month, we had a conversation today with Eoin Flanagan, of Mayo Clinic, who spoke to us about assessing the diagnostic utility of cerebrospinal fluid myelin oligodendrocyte glycoprotein antibodies testing. Stay tuned!

We begin MOG Antibody Disease Awareness Month by giving a short description and explanation of MOG antibody disease. How did you experience your initial symptoms? Share them with us by replying to this tweet. #MOGAD #ThisIsMogAntibodyDisease #ThisIsMOGAD

Please join us for the Mellen Center Update in #MultipleSclerosis #MS Cleveland Clinic on Friday June 21, 2024
#CLEClinicNeuro

To register ccfcme.org/MS

Therapeutic Potential of Transcranial Direct Current Stimulation in Primary Progressive #Aphasia : Leigh Charvet, PhD NeurologyLive® TheBrainDriver tDCS Peak Performance Technologies @cnbc #tDCS #BrainStimulation #Dementia
neurologylive.com/view/therapeut…

So proud of Dr Ailani and to be part of Georgetown Department of Neurology MedStar Georgetown GU Medical Center Georgetown Neurology Residency MedStar Washington American Academy of Neurology click on link 👇🏾

A group of experts in #MS discussed differences in immunologic phenotypes across racial boundaries. They also talked about data showing that, despite these differences, response to high-efficacy agents appears to be consistent regardless of race.

🗣️ neurologylive.com/view/pregnancy…

At #AANAM , a group of researchers from NYU Langone Health presented a study on the use of binocular visual measures of low-contrast letter acuity to distinguish patients with #MCI because of #AD and AD versus cognitively normal controls. American Academy of Neurology

neurologylive.com/view/understan…

🎙️The latest MEDcast episode features Drs Isaacson, Pahwa, and Gupta who discussed the management of dyskinesia and providing good ON time in #PD , sharing practical tips as well as their experience with current treatments.

View now: neurologylive.com/view/dyskinesi…

🎥 In a new Peer Exchange episode, expert #neurologists share approaches to switching #MG treatment because of either poor disease control or adverse events.

📺 Watch the new episode now: neurologylive.com/view/switching…

Watch Dr. Jessica Ailani, director of the MedStar Georgetown Headache Center, talk with NeurologyLive® at the American Academy of Neurology annual meeting about a migraine treatment that could offer long-term relief for most patients who respond well to the initial dose. ms.spr.ly/6019YyGFB

The DSF Family & Professional Conference, scheduled for June 20-22 in Bloomington, Minnesota, provides a comprehensive program for healthcare professionals to stay updated on clinical trials in #DravetSyndrome . Dravet Syndrome Foundation

Learn more at: dravetfoundation.org/events/dsf-con…

In new data from the phase 3 ASCLEPIOS I and II and ALITHIOS open-label extension studies, ofatumumab displayed sustained efficacy over 6 years in recently diagnosed, treatment-naïve relapsing #MS . #AANAM American Academy of Neurology Novartis OMRF Dr. Gabriel Pardo

📗 neurologylive.com/view/ofatumuma…

' #PIRA is condition that poses major unmet need.... Currently, there are no disease-modifying therapies approved for this category of progressive #MS ...This study provides initial evidence that this fully human anti-CD3 has potential to benefit this type of MS' ~Tarun Singhal, MD

While acute unilateral optic neuropathy with disc edema may be found in #MOGAD or #NAION , new data suggests detailed history, degree of peripapillary nerve fiber layer, and visual outcomes can differentiate the 2 conditions. Neurology Journal Nanthaya Tisavipat

neurologylive.com/view/researche…

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how technology is poised to transform the fight against #ParkinsonDisease , with the potential to improve millions of lives and advance health equity. #PDAwarenessMonth Parkinson's Foundation

📘 neurologylive.com/view/ai-revolu…

VIDEO: As we fade the lights on #SparktheNight I want to thank everyone who made it happen. Together we illuminated over 300 iconic buildings and landmarks casting a brilliant blue glow symbolizing hope, unity, and visibiltiy for the Parkinson's community. youtu.be/dbixVS-mOHg

For nearly 10 million patients worldwide, #ParkinsonDisease transforms precious sleep time into a battleground between exhaustion and #insomnia . 💤🌙 Larry Gifford AbbVie PD Avengers

Hear more from the patient perspective in honor of #PD Awareness Month: neurologylive.com/view/illuminat…

#ICYMI : Our latest #MindMoments podcast ep features a conversation w/ Ian Kremer, who discussed several Alzheimer-related topics, including the discontinuation of aducanumab and the promising therapies in development.

Listen here: neurologylive.com/view/episode-1…

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, review strategies for optimizing treatment of women with MD who are pregnant while minimizing risks.

neurologylive.com/view/pregnancy…

Cerevel Therapeutics’ investigational agent tavapadon, a selective D1/D5 receptor partial agonist in development for Parkinson disease, met its primary end point of change in ON time without troublesome dyskinesia in the phase 3 TEMPO-3 trial.

neurologylive.com/view/cerevel-t…